Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Mepolizumab

First report of recurrent pneumonia and squamous cell carcinoma: case report

    • 30 Accesses

    An event is serious (FDA MedWatch definition) when the patient outcome is:

    • death

    • life-threatening

    • hospitalisation

    • disability

    • congenital anomaly

    • requires intervention to prevent permanent impairment or damage

    First published case report

    A 46-year-old man with a history of asthma and atopic dermatitis, developed recurrent pneumonia and squamous cell skin carcinoma during treatment with mepolizumab for hypereosinophilic syndrome.

    The man started a trial of mepolizumab [route and dose not stated] in September 2005, concomitantly with systemic steroids. His condition improved after three monthly doses. Prednisone was withdrawn. However, due to multiple asthma exacerbations and a rise of his eosinophil count to 3000, he restarted prednisone in 2007. He resumed mepolizumab in 2008. Following improvement of his disease symptoms prednisone was discontinued. He developed pneumonia in his left lower lobe in December 2008, and in his right upper lobe 2 months later. His sputum was positive for Haemophilus influenza. He developed cough, fever and pneumonia with growth of Streptococcus pneumoniae during the following month. In 2009, he had three additional pneumonia episodes which resolved with antibiotics. Multiple sputum cultures grew Mycobacterium avium. He also developed eight squamous cell carcinomas on his skin throughout 2009. Mepolizumab was withdrawn, due to concerns of recurrent infection and skin cancer.

    FormalPara COMMENT

    Editorial Comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of pneumonia or squamous cell carcinoma associated with mepolizumab. The WHO ADR database contained two reports of pneumonia and none of squamous cell carcinoma associated with mepolizumab.

    FormalPara Key words

    Mepolizumab - Pneumonia - adverse reactions - drug-induced - Squamous-cell-cancer - Research-and-development

    REFERENCE

    1. 1.

      Shariat C, Fadel DA, Schattner G.Recurrent Pneumonias and Squamous Cell Carcinomas of the Skin During Treatment With Mepolizumab in a Patient With Hypereosinophilic Syndrome. 76th Annual Meeting of the American College of Chest Physicians: Chest 2010: 30 Oct 2010. Available from: URL: http://chestjournal.chestpubs.org - USA

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Mepolizumab. React. Wkly. 1329, 25 (2010). https://doi.org/10.2165/00128415-201013290-00082

    Download citation

    Keywords

    • Asthma
    • Influenza
    • Squamous Cell Carcinoma
    • Prednisone
    • Atopic Dermatitis